Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose modification.
Fields of Study & Subjects
Lymphoma Diagnosis and Treatment
CAR-T cell therapy research
Chronic Lymphocytic Leukemia Research
Publication details
- Journal / source
- Clinical Case Reports
- Volume
- 14
- Issue
- 4
- Pages
- e72234
- Publication date
- 30 March 2026
- Language
- EN